Literature DB >> 15029471

Sigma1 receptor upregulation after chronic methamphetamine self-administration in rats: a study with yoked controls.

Roman Stefanski1, Zuzana Justinova, Teruo Hayashi, Minoru Takebayashi, Steven R Goldberg, Tsung-Ping Su.   

Abstract

RATIONALE: Sigma(1) receptors (Sig-1R) are implicated in behavioral sensitization, conditioned place preference, and cellular restructuring induced by psychostimulants. We previously reported that rats which actively self-administered methamphetamine for 5 weeks and were then withdrawn from methamphetamine for 24 h showed downregulation of dopamine D(2) autoreceptors (approximately 30%) in the midbrain and this was not seen in rats that passively received injections of methamphetamine or saline at the same time (yoked controls). Involvement of Sig-1R in the self-administration of psychostimulants, however, has never been reported.
OBJECTIVES: This study examined neuroadaptive changes in Sig-1R in the brains of rats self-administering methamphetamine.
METHODS: Three groups of rats were tested simultaneously 5 days per week, for 5 weeks (25 daily sessions). Two groups served as yoked controls and passively received an injection of either 0.1 mg/kg methamphetamine or saline (not contingent on responding) each time a response-contingent injection of 0.1 mg/kg methamphetamine was actively self-administered by the first group of rats. Protein and mRNA levels of Sig-1R were then measured by Western and Northern blottings, respectively.
RESULTS: There was a marked upregulation of Sig-1R proteins (50%) in the midbrain and altered levels of Sig-1R mRNA in the frontal cortex and hippocampus of rats that learned to actively self-administer methamphetamine, but not in yoked methamphetamine- or saline-control rats.
CONCLUSIONS: Neuroadaptive increases in Sig-1R seen in this study may contribute to the reinforcing effects of methamphetamine. This upregulation of Sig-1R may be mediated by increased protein kinase A activity due to downregulation of dopamine D(2) autoreceptors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15029471     DOI: 10.1007/s00213-004-1779-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  30 in total

Review 1.  Neurobiology of relapse to heroin and cocaine seeking: a review.

Authors:  Uri Shalev; Jeffrey W Grimm; Yavin Shaham
Journal:  Pharmacol Rev       Date:  2002-03       Impact factor: 25.468

2.  Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons.

Authors:  Daniel Saal; Yan Dong; Antonello Bonci; Robert C Malenka
Journal:  Neuron       Date:  2003-02-20       Impact factor: 17.173

Review 3.  Neuroadaptations involved in amphetamine and cocaine addiction.

Authors:  F J White; P W Kalivas
Journal:  Drug Alcohol Depend       Date:  1998 Jun-Jul       Impact factor: 4.492

4.  Cocaine binding at sigma receptors.

Authors:  J Sharkey; K A Glen; S Wolfe; M J Kuhar
Journal:  Eur J Pharmacol       Date:  1988-04-27       Impact factor: 4.432

5.  Repeated methamphetamine-treatment alters brain sigma receptors.

Authors:  Y Itzhak
Journal:  Eur J Pharmacol       Date:  1993-01-12       Impact factor: 4.432

6.  Involvement of the sigma1 receptor in the cocaine-induced conditioned place preference.

Authors:  P Romieu; R Martin-Fardon; T Maurice
Journal:  Neuroreport       Date:  2000-09-11       Impact factor: 1.837

7.  Involvement of the sigma(1) receptor in cocaine-induced conditioned place preference: possible dependence on dopamine uptake blockade.

Authors:  Pascal Romieu; Vân Ly Phan; Rémi Martin-Fardon; Tangui Maurice
Journal:  Neuropsychopharmacology       Date:  2002-04       Impact factor: 7.853

Review 8.  Sigma(1) (sigma(1)) receptor antagonists represent a new strategy against cocaine addiction and toxicity.

Authors:  Tangui Maurice; Rémi Martin-Fardon; Pascal Romieu; Rae R Matsumoto
Journal:  Neurosci Biobehav Rev       Date:  2002-06       Impact factor: 8.989

Review 9.  Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems.

Authors:  B J Everitt; J A Parkinson; M C Olmstead; M Arroyo; P Robledo; T W Robbins
Journal:  Ann N Y Acad Sci       Date:  1999-06-29       Impact factor: 5.691

Review 10.  Psychomotor stimulant addiction: a neural systems perspective.

Authors:  Barry J Everitt; Marina E Wolf
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

View more
  39 in total

1.  The sigma receptor agonist SA4503 both attenuates and enhances the effects of methamphetamine.

Authors:  Kelli R Rodvelt; Clark E Oelrichs; Lucas R Blount; Kuo-Hsien Fan; Susan Z Lever; John R Lever; Dennis K Miller
Journal:  Drug Alcohol Depend       Date:  2011-02-01       Impact factor: 4.492

2.  Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure.

Authors:  Lisa M McFadden; Paula L Vieira-Brock; Glen R Hanson; Annette E Fleckenstein
Journal:  Neuropharmacology       Date:  2015-01-31       Impact factor: 5.250

3.  The sigma receptor: evolution of the concept in neuropsychopharmacology.

Authors:  T Hayashi; Tp Su
Journal:  Curr Neuropharmacol       Date:  2005-10       Impact factor: 7.363

Review 4.  Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Shang-Yi Tsai; Tomohisa Mori; Michiko Fujimoto; Tsung-Ping Su
Journal:  Expert Opin Ther Targets       Date:  2011-03-05       Impact factor: 6.902

5.  Self-administration of cocaine induces dopamine-independent self-administration of sigma agonists.

Authors:  Takato Hiranita; Maddalena Mereu; Paul L Soto; Gianluigi Tanda; Jonathan L Katz
Journal:  Neuropsychopharmacology       Date:  2012-11-28       Impact factor: 7.853

6.  Interactions between 3,4-methylenedioxymethamphetamine and sigma1 receptors.

Authors:  Matthew K Brammer; Deborah L Gilmore; Rae R Matsumoto
Journal:  Eur J Pharmacol       Date:  2006-09-28       Impact factor: 4.432

7.  The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.

Authors:  Melanie A Paquette; Katherine Foley; Elizabeth G Brudney; Charles K Meshul; Steven W Johnson; S Paul Berger
Journal:  Psychopharmacology (Berl)       Date:  2009-03-13       Impact factor: 4.530

8.  Regulation of sigma-1 receptors and endoplasmic reticulum chaperones in the brain of methamphetamine self-administering rats.

Authors:  Teruo Hayashi; Zuzana Justinova; Eri Hayashi; Gianfrancesco Cormaci; Tomohisa Mori; Shang-Yi Tsai; Chanel Barnes; Steven R Goldberg; Tsung-Ping Su
Journal:  J Pharmacol Exp Ther       Date:  2009-11-25       Impact factor: 4.030

9.  The sigma-receptor antagonist BD-1063 decreases ethanol intake and reinforcement in animal models of excessive drinking.

Authors:  Valentina Sabino; Pietro Cottone; Yu Zhao; Malliga R Iyer; Luca Steardo; Luca Steardo; Kenner C Rice; Bruno Conti; George F Koob; Eric P Zorrilla
Journal:  Neuropsychopharmacology       Date:  2008-10-22       Impact factor: 7.853

10.  Pharmacology and therapeutic potential of sigma(1) receptor ligands.

Authors:  E J Cobos; J M Entrena; F R Nieto; C M Cendán; E Del Pozo
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.